Regulation — pharma-specific

ICH E6(R3) GCP — essential-documents duty on AI-driven eligibility records

The 2023 R3 revision moved GCP toward a quality-by-design + risk-based-monitoring frame. Any technology — AI included — participating in eligibility decisions falls inside essential-documents scope. Sponsors that treat AI screening output as "vendor telemetry" instead of essential records mis-locate the duty.

What the guideline actually says

"Sponsors should implement a system to manage quality throughout all stages of the trial process … The methods used to assure and control the quality of the trial should be proportionate to the risks … and the importance of the information collected." ICH E6(R3) — sponsor quality-management expectation (2023 revision, effective 2025-2026)

"Essential documents are those documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced." ICH E6(R2) §8 — essential-documents definition (retained under R3)

What this means in plain English

Two GCP principles that apply directly when AI participates in eligibility screening:

Quality-by-design. Risk to trial-participant safety + data integrity dictates the level of monitoring. High-impact decisions (eligibility inclusion/exclusion) need proportionately strong monitoring.
Essential-documents scope. Records that let a reviewer evaluate trial conduct and data quality must be retained. AI screening decisions that route participants in or out satisfy that definition on their face.

ICH E6(R3) does not say "AI is exempt from GCP." It says the sponsor's quality system must be proportionate to risk — which for AI-driven eligibility is high.

What triggers the exposure in the sample

10 high-severity distributional-drift events + a 53 percentage-point P3 exclude-lane shift is high-risk under the E6(R3) proportionality frame. Sponsor quality-management + essential-documents duty apply to every affected eligibility decision through trial conclusion and the post-marketing horizon.

What the $499 Snapshot shows against this rule

Risk-based-monitoring evidence — independent-verifier monitoring proportionate to the eligibility-decision risk profile
Essential-documents scope confirmation — AI-decision records inside the retention perimeter
3 fix-first items scoped to sponsor quality-management — the "system to manage quality" restart
Signed declaration — independent monitoring documented, dated, retained

See the reproducibility drill against essential-documents duty →

How does this help me?

ICH E6(R3) is what an EMA scientific-advice rapporteur, FDA BIMO inspector, or IRB continuing-review board applies when asking "what's your sponsor quality-management for the trial AI?" Having an independent record on file changes the answer.

Read: ICH E6(R3) -- what it saves you in inspection + scientific-advice conversations →

$499 Snapshot. 3 business days.

Independent-verifier determination scoped to your sponsor's AI surface + 3 fix-first items + signed declaration.

Buy $499

Snapshot credit applies to Baseline ($2,500) or Enterprise Attestation ($35-55K) upgrade within 30 days.